FierceBiotech· @FierceBiotech · X·· 12 天前精选AI 评分58
AI 导读
Evommune与中国海创药业(Hinova Pharmaceuticals)达成一项最高价值11亿美元的交易,加入诺华所在的VAV1靶向分子胶降解剂研发赛道。交易具体条款未在材料中披露。
推荐理由
这笔最高11亿美元的授权交易,让读者看到VAV1分子胶降解剂赛道又添一家入局者。
正文
Evommune is joining Novartis in the race to develop VAV1-targeting molecular glue degraders, striking a deal worth up to $1.1 billion with China's Hinova Pharmaceuticals. https://www.fiercebiotech.com/biotech/evommune-signs-1b-deal-chinas-hinova-enter-same-molecular-glue-space-novartis
来源:FierceBiotech · x.com